BusinessNew CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque psoriasis and psoriatic arthritis presented at American Academy of Dermatology 2017 Annual MeetingBy Nasdaq OMXMar 4, 2017, 2:00 PM UTC
BusinessDermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual MeetingBy Nasdaq OMXMar 3, 2017, 1:24 PM UTC
BusinessDermira to Present at Cowen and Company 37th Annual Health Care ConferenceBy Nasdaq OMXMar 2, 2017, 9:05 PM UTC
BusinessDermira Prices $168.5 Million Public Offering of Common StockBy Nasdaq OMXMar 2, 2017, 12:47 AM UTC
BusinessDermira Announces Proposed Public Offering of Common StockBy Nasdaq OMXFeb 28, 2017, 10:14 PM UTC
BusinessDermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdateBy Nasdaq OMXFeb 28, 2017, 9:07 PM UTC
BusinessDermira to Present at Leerink Partners 6th Annual Global Healthcare ConferenceBy Nasdaq OMXFeb 8, 2017, 9:05 PM UTC
BusinessFinal CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque PsoriasisBy Nasdaq OMXJan 19, 2017, 7:00 AM UTC
